Proteome Sciences PLC 2021 AR2
The report outlines Proteome Sciences plc's financial and operational performance for the fiscal year 2021. Despite the ongoing challenges of the COVID-19 pandemic, the company achieved an 8% increase in group revenues to #5.13m, driven by strong growth in its biomarker services business. Proteome Sciences made strategic investments in new equipment and staff to expand capacity, including the installation of a new mass spectrometer. The company also successfully introduced a new SysQuant workflow for analyzing ubiquitin-modified proteins and evaluated the feasibility of single-cell proteomics.
Company: Proteome Sciences PLC
Sector: Professional & technical services
Country: United Kingdom
Year: 2021
Type: AR2
Pages: 89
Back to company
Proteome Sciences PLC
Report And Financial Statements
The report outlines Proteome Sciences plc's financial and operational performance for the fiscal year 2021. Despite the ongoing challenges of the COVID-19 pandemic, the company achieved an 8% increase in group revenues to #5.13m, driven by strong growth in its biomarker services business. Proteome Sciences made strategic investments in new equipment and staff to expand capacity, including the installation of a new mass spectrometer. The company also successfully introduced a new SysQuant workflow for analyzing ubiquitin-modified proteins and evaluated the feasibility of single-cell proteomics.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees